Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Liabilities and Shareholders Equity: 2015-2024

Historic Liabilities and Shareholders Equity for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $1.2 billion.

  • Intellia Therapeutics' Liabilities and Shareholders Equity fell 21.14% to $925.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year decrease of 18.76%. This contributed to the annual value of $1.2 billion for FY2024, which is 8.45% down from last year.
  • Per Intellia Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $1.2 billion for FY2024, which was down 8.45% from $1.3 billion recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Liabilities and Shareholders Equity ranged from a high of $1.5 billion in FY2022 and a low of $676.3 million during FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.3 billion, with a median of $1.3 billion in 2023.
  • In the last 5 years, Intellia Therapeutics' Liabilities and Shareholders Equity skyrocketed by 102.32% in 2020 and then fell by 14.42% in 2023.
  • Intellia Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $676.3 million in 2020, then surged by 91.40% to $1.3 billion in 2021, then climbed by 17.43% to $1.5 billion in 2022, then declined by 14.42% to $1.3 billion in 2023, then decreased by 8.45% to $1.2 billion in 2024.